Fgf-9 and its use relating to blood vessels

ABSTRACT

There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising a first isolated nucleic acid molecule that encodes a FGF-9 polypeptide and optionally one or more isolated nucleic acid molecule that encodes another angiogenic polypeptide. There is provided a composition for controlling formation and/or stabilization of a blood vessel comprising administering an effective amount of a composition comprising an isolated FGF-9 polypeptide and one or more other angiogenic polypeptides. The compositions provided herein may be useful for controlling angiogenesis and/or vasculogenesis.

FIELD OF THE INVENTION

The present invention relates to controlling formation and/orstabilization of blood vessels. More particularly, the present inventionrelates to use of a FGF9 molecule for controlling formation and/orstabilization of blood vessels

BACKGROUND OF THE INVENTION

The development of new blood vessels (angiogenesis) is fundamental notonly during embryogenesis but also as a protective response in adulttissue subjected to ischemia. To be productive, the formation ofendothelial lined vessels is typically followed by the recruitment ofperivascular cells. This maturation process produces functional vesselswhich persist over time and are responsive to physiological stimuli. Theproduction of mature vessels is of therapeutic importance in thetreatment of ischemic disease. However, there has been little success instimulating the formation of mature microvessels in adults.

Angiogenesis is a physiological process involving the growth of newblood vessels from pre-existing vessels. Angiogenesis entails theproliferation and migration of endothelial cells to form immaturevascular networks. There is also a maturation phase of angiogenesis thatentails the recruitment of mesenchymal cells, including pericytes and/orsmooth muscle cells (SMCs), which wrap the newly formed vessels tostabilize them. This is referred to as angiogenic maturation. Suchangiogenic maturation may be the process of a recent angiogenic event,or include maturation, maintenance, and stabilization of vesselsgenerated through angiogenesis at any point in development andpost-natally. Angiogenic maturation may also include the process ofmaturation, supporting, and stabilizing of blood vessels generatedthrough the process of vasculogenesis as defined by the de novocondensation of appropriate stem, progenitor, or more differentiatedcell types into tubular vessels.

A number of proteins, typically referred to as angiogenic proteins, areknown to promote angiogenesis. Such angiogenic proteins include membersof the fibroblast growth factor (FGF) family, the vascular endothelialgrowth factor (VEGF) family, the platelet-derived growth factor (PDGF)family, or the insulin-like growth factor (IGF) family. For example,certain FGF and VEGF family members have been recognized as regulatorsof angiogenesis during growth and development. Their role in promotingangiogenesis in adult animals has also been examined.

Angiogenic proteins, such as FGF family members, have been disclosed inmany patent documents, for example U.S. Pat. No. 4,956,455 (titledBovine fibroblast growth factor, issued Sep. 11, 1990), U.S. Pat. No.5,155,214 (titled Basic fibroblast growth factor, issued Oct. 13, 1992),U.S. Pat. No. 5,302,702 (titled Chimeric fibroblast growth factors,issued Apr. 12, 1994), U.S. Pat. No. 5,314,872 (titled: Glucan sulfate,stabilized fibroblast growth factor composition, issued May 24, 1994),U.S. Pat. No. 5,352,589 (titled Deletion mutant of basic fibroblastgrowth factor and production thereof, issued Oct. 4, 1994), U.S. Pat.No. 5,371,206 (titled DNA encoding chimeric fibroblast growth factors,issued Dec. 6, 1994), U.S. Pat. No. 5,387,673 (titled Active fragmentsof fibroblast growth factor, issued Feb. 7, 1995), U.S. Pat. No.5,439,818 (titled DNA encoding human recombinant basic fibroblast growthfactor, issued Aug. 8, 1995), U.S. Pat. No. 5,491,220 (titled Surfaceloop structural analogues of fibroblast growth factors, issued Feb. 13,1996), U.S. Pat. No. 5,514,566 (titled Methods of producing recombinantfibroblast growth factors, issued May 7, 1996), U.S. Pat. No. 5,604,293(titled Recombinant human basic fibroblast growth factor, issued Feb.18, 1997).

The fibroblast growth factors (FGF) are a family of at leasttwenty-three structurally related polypeptides (named FGF1 to FGF23)that are characterized by a high degree of affinity for proteoglycans,such as heparin. The various FGF molecules range in size from 15-23 kD,and exhibit a broad range of biological activities in normal andmalignant conditions. Activities that have been characterized for FGFmolecules include nerve cell adhesion and differentiation; woundhealing; as mitogens toward many mesodermal and ectodermal cell types,as trophic factors, as differentiation inducing or inhibiting factors:and as an angiogenic factor. For example, PCT Publication WO98/50079(titled Techniques And Compositions For Treating Heart Failure AndVentricular Remodeling By In Vivo Delivery Of Angiogenic Transgenes,published Dec. 30, 2004) describes the use of FGF2, FGF4, or FGF5 toameliorate regional myocardial contractile dysfunction in an animalmodel of heart failure. The therapeutic mechanism of action is stated tobe angiogenesis.

Angiogenesis entails the proliferation and migration of endothelialcells from the existing vasculature in order to create new bloodvessels. These nascent vessels are incomplete as they lack supportinglayers of mature smooth muscle cells (SMCs). As a result, immaturevascular beds are prone to regression due to the fact that endothelialcells retract and eventually undergo apoptosis. Stabilization of newlyor previously formed blood vessels through angiogenic maturation by SMCsboth prevents regression while also conferring the critical ability toregulate blood pressure. While a number of factors that stimulate therecruitment of SMCs to blood vessels during development have beenidentified, these pathways are poorly understood with respect topostnatal angiogenesis.

Currently, blood vessel formation stimulated by established solubleangiogenic cytokines either in vivo or simulated in vitro areshort-lived due to the fact that they lack complete layers of supportingSMCs and are therefore of limited therapeutic or experimental value.

SUMMARY OF THE INVENTION

The invention provides compositions and methods to promote angiogenesismaturation and stabilization. It is herein first demonstrated thatcompositions comprising FGF-9 and one or more other angiogenicpolypeptides can be used in vitro and in vivo to promote, control andstabilize blood vessel formation. This includes the improvement of bloodvessel condition of existing blood vessels. As such, the invention haswide application and utility as a culture supplement for in vitroculture of cells and/or tissues. The invention also has wide therapeuticapplication in clinical conditions where angiogenesis is required or isbeneficial to provide stabilized blood vessels, in any of theembodiments of the invention the invention can be provided a compositionfor systemic or local administration with or without a carrier orcarrier matrix.

According to an aspect of the present invention there is provided amethod of promoting blood vessel formation in hypoxic or ischemictissues in a patient in need thereof, comprising contacting said tissuewith a composition comprising FGF-9 polypeptide and one or more otherisolated angiogenic polypeptide.

According to another aspect of the present invention is a method oftreating a condition amenable to treatment by promoting angiogenesis,said method comprising administering to a subject in need thereof anamount of a FGF-9 polypeptide composition comprising FGF-9 and one ormore other angiogenic polypeptides, effective for promoting angiogenesisin said subject.

According to a further aspect of the present invention is a method forimproving the condition of a blood vessel, such improvement comprisingthe proliferation and migration of endothelial cells to form immaturevascular networks, and the recruitment of mesenchymal cells, includingpericytes and/or smooth muscle cells (SMCs) to wrap the vessels tostabilize them and thus improve their condition, the method comprisingcontacting the blood vessel with a composition comprising FGF-9 and oneor more other angiogenic factor(s).

In an aspect, there is provided a composition for controlling formationand/or stabilization of a blood vessel comprising a first isolatednucleic acid molecule that encodes a FGF-9 polypeptide and optionally asecond isolated nucleic acid molecule that encodes another angiogenicpolypeptide. In aspects, the nucleic acid molecule can be DNA, RNA,single or double-stranded.

In another aspect, there is provided a composition for controllingformation and/or stabilization of a blood vessel comprising an isolatedFGF-9 polypeptide and optionally one or more other angiogenicpolypeptides.

In another aspect, there is provided a composition for stabilizingexisting blood vessels in need of such treatment, the compositioncomprising an isolated FGF-9 polypeptide and one or more angiogenicpolypeptides.

In yet another aspect, there is provided a composition for controllingformation and/or stabilization of a blood vessel comprising arecombinant cell producing an isolated FGF-9 polypeptide and optionallyanother isolated angiogenic polypeptide.

In a further aspect, there is provided a composition for promotingtherapeutic angiogenesis in an animal comprising a first isolatednucleic acid molecule that encodes a FGF-9 polypeptide and a secondisolated nucleic acid molecule that encodes an angiogenic polypeptide.

In still a further aspect, there is provided a composition for promotingtherapeutic angiogenesis in an animal comprising an isolated FGF-9polypeptide and another angiogenic polypeptide.

In an even further aspect, there is provided a composition for promotingtherapeutic angiogenesis in an animal comprising a recombinant cellproducing an isolated FGF-9 polypeptide and another isolated angiogenicpolypeptide.

In another aspect, there is provided a method of promoting formation ofmature blood vessels in a subject comprising administering an effectiveamount of FGF-9 to the subject.

In still another aspect, there is provided a method of treating ischemiain a subject comprising administering an effective amount of FGF-9 tothe subject.

In yet another aspect, there is provided a use of FGF-9 for preparationof a medicament.

In still yet another aspect, there is provided a use of FGF-9 forpreparation of a medicament for promoting formation of mature bloodvessels in a subject or improving the condition of an existing bloodvessel

In another aspect, there is provided a use of FGF-9 for preparation of amedicament for treating ischemia in a subject.

In even another aspect, there is provided a use of FGF-9 for promotingformation of mature blood vessels in a subject.

In still another aspect, there is provided a use of FGF-9 for treatingischemia in a subject.

In a further aspect, there is provided a kit comprising FGF-9 and amatrix material, and instructions for preparing an in vitrovasculogenesis assay.

In accordance with a further aspect, there is provided a kit comprisinga FGF-9 containing composition and a matrix material, with instructionsfor use and for preparing an in vitro angiogenesis assay.

In still a further aspect, there is provided an in vitro vasculogenesisassay comprising a matrix material, FGF-9, endothelial cells, smoothmuscle cells, and a matrix material for supporting growth andproliferation of cells.

In yet a further aspect, there is provided a use of FGF-9 forstabilization of blood vessels in vitro or in vivo.

In yet a further aspect of the invention, there is provided a FGF-9containing composition for the promotion of the angiogenenic maturationof blood vessels in vitro or in vivo.

In another aspect, there is provided a use of FGF-9 for treatment ofcancer.

Other features and advantages of the present invention will becomeapparent from the following detailed description. It should beunderstood, however, that the detailed description and the specificexamples while indicating embodiments of the invention are given by wayof illustration only, since various changes and modifications within thespirit and scope of the invention will become apparent to those skilledin the art from said detailed description.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention will become more fully understood from thedetailed description given herein and from the accompanying drawings,which are given by way of illustration only and do not limit theintended scope of the invention as herein described in its variousembodiments.

FIG. 1 shows mRNA coding region sequence and corresponding amino acidsequence for mammalian FGF-9A) Homo sapiens (NCBI gi:391718), B) Musmusculus (NCBI gi:1161346), C) Rattus norvegicus (NCBI gi:391852);

FIG. 2 shows a multiple sequence alignment of Human, Mouse, Rat, and PigFGF-9 amino acid sequences;

FIG. 3 shows steps in a high throughput screen for secreted by SMCs asthey acquire specialized functions;

FIG. 4 shows that FGF-9 is upregulated as SMCs acquired specializedfunctions;

FIG. 5 shows that FGF-9 does not initiate the angiogenic process insubcutaneously implanted matrigel in mice;

FIG. 6 shows that FGF-9 stimulates recruitment of SM α-actin expressingmural cells to nascent microvessels during angiogenesis;

FIG. 7 shows that FGF-9 stimulates SM α-actin expressing mural cellsrecruitment along continuous lengths of blood vessels;

FIG. 8 shows that FGF-9 stimulates circumferential wrapping of bloodvessels by SM α-actin expressing mural cells;

FIGS. 9A-C shows that FGF-9 modified microvessels are responsive tovasoactive stimuli and can vasoconstrict and vasodilate;

FIG. 10 shows that FGF-9-stimulated wrapping may be dependent on theupregulation of PDGFR-β;

FIG. 11 shows vasculogenesis in an in vitro matrigel assay withendothelial and smooth muscle cells;

FIG. 12 shows that FGF-9 stabilizes the neovasculature;

FIG. 13 shows that FGF-9 stimulates the recruitment of nerves to theneovasculature;

FIG. 14 shows that FGF-9-stimulated wrapping is dependent on theupregulation of PDGFR-β;

FIG. 15 shows that FGF-9-mediated PDGFR-β upregulation and vesselmaturation requires Sonic Hedgehog signaling;

FIG. 16 shows the in vitro direct effects of FGF-9 on SMCs in culture;

FIG. 17 shows the proposed mechanism of action for FGF-9 duringangiogenesis;

FIG. 18 shows a cancer model using a kidney carcinoma cell line todemonstrate the “tightening” of the blood vessel to prevent metastasisfrom primary tumors to distal sites.

FIG. 19 shows in vitro co-culture and tubule formation using FGF-9; and

FIG. 20 shows that FGF-9 results in increased association of SMCs withendothelial tubes.

DETAILED DESCRIPTION OF THE EMBODIMENTS

For convenience, before further description of the present invention,certain terms employed in the specification, examples, and appendedclaims are provided herein. These definitions should be read in light ofthe remainder of the disclosure and understood as by a person of skillin the art. Also, the terms “including” (and variants thereof), “suchas”, “e.g.” as used herein are non-limiting and are for illustrativepurposes only. The articles “a” and “an” are used herein to refer to oneor to more than one (i.e. to at least one) of the grammatical object ofthe article. By way of example, “an element” means one element or morethan one element. The term “angiogenesis” is an art-recognized term, andrefers to the process and creation of new blood vessels formed frompre-existing blood vessels. The term “restenosis” refers to are-narrowing of a blood vessel, thereby restricting blood flow. Thisre-narrowing can be caused by, for example, a vessel's response to aninjury inflicted during balloon angioplasty. The term “hypoxic tissue”refers to tissue with an insufficient amount of oxygen. The term“ischemic tissue” refers to tissue with insufficient blood flow.

All publications and patents mentioned herein, including those itemslisted below, are hereby incorporated by reference in their entirety asif each individual publication or patent was specifically andindividually indicated to be incorporated by reference.

Methods and compositions for controlling formation and/or stabilizationof blood vessels are described herein. More specifically, methods andcompositions for controlling angiogenesis and/or vasculogenesis aredescribed herein.

Angiogenesis is a physiological process involving the growth of newblood vessels from pre-existing vessels. One aspect of angiogenesisentails the proliferation and migration of endothelial cells to formimmature vascular networks. Another aspect of angiogenesis is amaturation phase that entails the recruitment of mesenchymal cells,including pericytes and/or smooth muscle cells (SMCs) that wrap vesselsto stabilize them. This is referred to as angiogenic maturation. Suchangiogenic maturation may be the process of a recent angiogenic event,or include maturation, maintenance, and stabilization of vesselsgenerated through angiogenesis at any point in development andpost-natally. Thus, angiogenic maturation may occur independently of theaspect of angiogenesis pertaining to formation of nascent or immatureblood vessels, and therefore may be beneficial in stabilizing any bloodvessel, nascent or otherwise. For example existing blood vessels in anadult animal that exhibit vascular leakage, or are at risk of exhibitingvascular leakage, can be stabilized by the process of angiogenicmaturation. Angiogenic maturation may also include the process ofmaturation, supporting, and stabilizing of blood vessels generatedthrough the process of vasculogenesis in vitro and/or in vivo.Vasculogenesis comprises de novo condensation of appropriate stem,progenitor, or more differentiated cell types into tubular vessels.

An angiogenic molecule is meant to encompass nucleic acids,polypeptides, small molecule chemical compounds or any other moleculethat can be used to control at least one aspect of angiogenesis. Forexample, an angiogenic polypeptide is a polypeptide that can be used tocontrol at least one aspect of angiogenesis. Angiogenic polypeptideshave been identified from many naturally occurring sources and variantsthereof have also been produced and characterized. Such angiogenicpolypeptides include members of the fibroblast growth factor (FGF)family (for example FGF-1, FGF-2, FGF-4, FGF-5, FGF-6, or FGF-9), thevascular endothelial growth factor (VEGF) family (for example VEGF-121,VEGF-145, VEGF-165, VEGF-167, VEGF-186, VEGF-189, VEGF-206, or VEGF-C),the platelet-derived growth factor (PDGF) family (for example PDGF-α orPDGF-β), or the insulin-like growth factor (IGF) family. Othernon-limiting examples of angiogenic peptides include PIGF, Hedgehogfamily member (Sonic, Indian and Desert), and SDF-1.

Angiogenic molecules may be used to prepare compositions that are usefulfor controlling at least one aspect of angiogenesis. Such compositionsmay be useful in any method, in vivo or in vitro, where formation and/orstabilization of a blood vessel is desired. Stabilization of bloodvessels may be useful in forming or maintaining blood vessels, forexample, by reducing regression of newly formed vessels, maintaining orconferring responsiveness to vasoactive stimuli, reduction of vascularleakage or formation of tight junctions. Stabilization of blood vesselsmay be useful in respect of both angiogenesis or vasculogenesis.

Compositions and methods described herein will comprise a FGF molecule,and more typically a FGF polypeptide.

In one example, compositions comprising a FGF-9 molecule are provided.

Without wishing to be bound by theory FGF-9 is believed to controlstabilization and/or formation of blood vessels or control angiogenesisand/or vasculogenesis by influencing migration of mesenchymal cells toblood vessels. The mesenchymal cells can provide stability to a bloodvessel by physical contact and more specifically by circumferentialwrapping of blood vessels. The blood vessels may be nascent or may be atany level of development or maturity.

Compositions comprising a FGF-9 molecule may be useful to controlangiogenesis. Compositions comprising a FGF-9 molecule may be useful topromote maturation of blood vessels during angiogenesis. Compositionscomprising a FGF-9 molecule may also be useful to promote formation offunctional blood vessels during angiogenesis. Compositions comprising aFGF-9 molecule may also be useful for recruitment of smooth musclealpha-actin positive cells to nascent blood vessels during angiogenesis.Compositions comprising a FGF-9 molecule may also be useful for inducingexpression of smooth muscle alpha-actin in mural cell precursors.Compositions comprising a FGF-9 molecule may also be useful to promotethe formation and/or maturation and/or stabilization of functional bloodvessels during vasculogenesis including stimulation of re-innervaton ofblood vessels. Compositions comprising a FGF-9 molecule may also beuseful for therapeutic angiogenesis, for example in treatment ofischemia by stimulating creation of new functional blood vessels inischemic organs, tissues or parts to increase the level of oxygen-richblood reaching these areas.

Compositions comprising a FGF-9 molecule may be used to treat anydisease or condition where the formation of new blood vessels provides aprophylactic and/or therapeutic benefit in absence of existingextracellular structure. Accordingly, a method for controllingangiogenesis in a subject comprises administering a compositioncomprising a FGF-9 molecule and another angiogenic agent in combinationwith a natural or synthetic or natural-synthetic combination ofextracellular matrix as a therapeutic biomaterial. The FGF-9 moleculemay be administered systemically or locally in a region wheretherapeutic angiogenesis is needed to facilitate angiogenesis within theappropriate extracellular structure as would be required for therapeutictissue engineering.

Compositions comprising a FGF-9 molecule may be used to treat anydisease or condition where the formation of new blood vessels provides aprophylactic and/or therapeutic benefit. Accordingly, a method forcontrolling angiogenesis in a subject comprises administering acomposition comprising a FGF-9 molecule. In another example, a methodfor treating ischemia in a subject comprises administering a compositioncomprising a FGF-9 molecule. The FGF-9 molecule may be administeredsystemically or locally in a region where therapeutic angiogenesis isneeded to treat ischemia.

Ischemia can be described as an inadequate flow of blood to a part ofthe body, caused by constriction or blockage of the blood vesselssupplying it, with resultant damage or dysfunction to this part of thebody. Ischemia is a well known feature of heart diseases, transientischemic attacks, cerebrovascular accidents, ruptured arteriovenousmalformations, and peripheral artery occlusive disease. The heart, thekidneys, and the brain are among the organs that are the most sensitiveto inadequate blood supply. Ischemia in brain tissue, for example due tostroke or head injury, causes a process called the ischemic cascade tobe unleashed, in which proteolytic enzymes, reactive oxygen species, andother harmful chemicals damage and may ultimately kill brain tissue.Ischemia to the heart can cause angina (CIP), which is sometimesdebilitating and refractory to current forms of therapy. Ischemia to theheart can also lead to heart muscle injury and muscle death (myocardialinfarction).

Ischemia to the lower limbs is also common in diabetes and can causerefractory lower limb pain (claudication) and lead to gangrene andamputation.

Compositions comprising a FGF-9 molecule may be used to treat anydisease or condition where the stabilization or angiogenic maturation ofexisting blood vessels provides a prophylactic and/or therapeuticbenefit. Accordingly, a method for controlling angiogenesis in a subjectcomprises administering a composition comprising a FGF-9 molecule. Inanother example, a method for treating vascular leakage in a subjectcomprises administering a composition comprising a FGF-9 molecule. TheFGF-9 molecule may be administered systemically or locally in a regionwhere therapeutic angiogenic maturation is needed to treat or mitigaterisk in a patient.

Vascular leakage can be described as the unregulated movement ofmolecules, such as proteins, toxins, and oxidized molecules, out of theblood to the nearby tissues. This leakage can lead to the damage anddeath of local cells. This is a prominent feature of diabeticretinopathy, which can lead to blindness. It may also be a feature ofneurological disorders such as Lou Gehrig's disease and Alzheimer'sdisease. When severe vascular leakage is accompanied by extravasation ofred blood cells and other circulating cells. This is referred to ashemorrhage. Hemorrhage from small vessels can have severe consequencesfor tissues such as the brain and the eye.

In a further embodiment of the invention, the compositions as describedherein have utility in the field of cancer for the treatment thereof.The administration of FGF-9 compositions of the invention may be usedfor stabilizing angiogenesis in tumours and effectively causing alocalization of the cancer and less metastases such that the tumour canbe more readily excised from the patient. In this aspect, the tumour maybe directly targeted with local administration of the FGF-9 containingcompositions of the invention. Alternatively, the FGF-9 containingcompositions of the invention may be administered systemically and/orlocally for reduction in metastases of cancerous cells throughout thebody. It is expected that tumours so treated will be more readilyexcisable from the patient with less chance of tumour metastases.

Compositions comprising a FGF-9 molecule and another angiogenic moleculemay be used in combination with vascular endothelial cells and vascularsmooth muscle cells with or without appropriate other cell types togenerate individual, a system, or a network of stabilized blood vesselsin vitro. In such cases, the existence of stabilized blood vessels wouldbe of benefit for research and development purposes, evaluation ofpotential therapeutic compounds, or in assessing the activity ofmodified cells in blood vessel formation or angiogenesis forexperimental purposes. Accordingly, a method for controllingangiogenesis in vitro comprises administering a composition comprising aFGF-9 molecule and another angiogenic molecule in a range ofconcentrations appropriate for inducing vessel formation and maturationwith a suitable culture medium.

In another non-limiting example, such a method for generating stabilizedblood vessels in vitro for the described purposes may benefit from theformation of 3-dimensional structures. Accordingly, for the generationof such 3 dimensional vascular structures such culture medium mayinclude a composition of FGF-9 and another angiogenic molecule at anappropriate concentration to generate stabilized blood vessels; anextracellular matrix that may include but are not limited to suchfactors as fibrin, Matrigel, collagen, hyaluronic acid, proteoglycans,derivatives thereof or synthetic structural agents; and may or may notcontain a natural or synthetic cross linking agent to generate the threedimensional structure.

Without wishing to be limited by theory, FGF-9 molecules appear topromote formation of functional blood vessels by influencing acontractile phenotype in smooth muscle cells and stimulating theirrecruitment to nascent blood vessels. A fundamental characteristic ofvascular smooth muscle cells is their ability to convert betweenimmature, proliferative and mature, contractile phenotypes. One processthat requires this plasticity is angiogenesis where smooth muscle cellsmust proliferate and migrate to nascent microvessels. Smooth musclecells must then wrap around these microvessels and reacquire the abilityto contract in order to stabilize the nascent culture. Using a uniquesmooth muscle cell-line that reversibly converts between immature andmature phenotypes, secreted factors that may regulate the stabilizationof neovessels have been identified. High density microarray analysis ofmaturing smooth muscle cells revealed only 27 secreted factors wereupregulated with FGF-9 being the most upregulated. In contrast otherFGFs showed no change (FGF-7,-11,-12,-14,-18) or were downregulated(FGF-1,-2,-5) as smooth muscle cells matured.

Without limitation, the FGF-9 molecule may be a full-length naturallyoccurring polypeptide or a variant thereof, or may be a nucleic acidmolecule encoding a FGF-9 polypeptide or variant thereof. Furthermore, arecombinant cell producing the FGF-9 molecule is provided.

An FGF-9 polypeptide may be provided by any source or method, forexample, natural isolate or recombinant or synthetic origin or suitablecombinations thereof. Administration of the FGF-9 polypeptide to asubject can be used to control angiogenesis, and more specifically topromote recruitment of smooth muscle cells during angiogenesis. TheFGF-9 polypeptide may be of any length provided that its angiogenicactivity is maintained. The sequence of the FGF-9 polypeptide may bebased on a complete or partial naturally occurring amino acid sequence.An FGF-9 polypeptide may be used either singly or in combination withother polypeptides, angiogenic or otherwise, in the preparation of acomposition that controls angiogenesis. A polypeptide refers to a chainof amino acids, for example peptides, oligopeptides, or proteins, havinga biological function, and does not refer to a specific length of thechain.

An isolated FGF-9 polypeptide is a polypeptide that has been identifiedand separated and/or recovered from at least one component of itsnatural environment. The isolated polypeptide will typically have beenpurified by at least one purification step, and, in some embodimentspurification may be achieved (1) to a degree sufficient to obtain atleast 15 residues of N-terminal or internal amino acid sequence by useof a sequenator, or (2) to homogeneity by SDS-PAGE under non-reducing orreducing conditions using Coomassie blue or, preferably, silver stain.Isolated polypeptide includes polypeptide in situ within recombinantcells, since at least one component of the FGF-9 polypeptide naturalenvironment will not be present. An isolated polypeptide may be producedby synthetic or recombinant techniques, for example as described in J.Sambrook, E. F. Fritsch, and T. Maniatis, 1989, Molecular Cloning: ALaboratory Manual, Second Edition, Books 1-3, Cold Spring HarborLaboratory Press. An isolated polypeptide produced as a result ofrecombinant techniques may be referred to as a recombinant polypeptide.

A nucleic acid encoding an FGF-9 polypeptide may be any nucleic acidmolecule of, for example. cDNA, genomic DNA, synthetic DNA or RNA originor suitable combinations thereof. Administration of the nucleic acidencoding an FGF-9 polypeptide to a subject can be used to controlangiogenesis, and more specifically to promote recruitment of smoothmuscle cells during angiogenesis. The nucleic acid may be of any lengthprovided that the angiogenic activity is maintained by the encoded FGF-9polypeptide. The sequence of the nucleic acid encoding an FGF-9polypeptide may be based on a complete or partial naturally occurringnucleic acid sequence. A nucleic acid sequence encoding an FGF-9polypeptide may be used either singly or in combination with othernucleic acid sequences, encoding angiogenic polypeptides or encoding anyother desired polypeptide, in the preparation of a composition tocontrol angiogenesis.

An isolated nucleic acid molecule encoding a FGF-9 polypeptide is anucleic acid molecule that is identified and separated from at least onecontaminant nucleic acid molecule with which it is ordinarily associatedin the natural source of the nucleic acid. Such an isolated nucleic acidmolecule is other than in the form or setting in which it is found innature. Isolated nucleic acid molecules therefore are distinguished fromthe nucleic acid molecule as it exists in natural cells. An isolatednucleic acid molecule encoding a FGF-9 polypeptide includes nucleic acidmolecule encoding a FGF-9 polypeptide contained in cells that ordinarilyexpress the FGF-9 polypeptide where, for example, the nucleic acidmolecule is in a chromosomal or extrachromosomal location different fromthat of natural cells. The isolated nucleic acid molecule may bereferred to as a recombinant nucleic acid molecule where the isolatednucleic acid molecule has been manipulated using recombinant techniques,for example, as described in J. Sambrook, E. F. Fritsch, and T.Maniatis, 1989, Molecular Cloning: A Laboratory Manual, Second Edition,Books 1-3, Cold Spring Harbor Laboratory Press.

Variants include, without limitation, analogs, derivatives, fragments,truncations, splice variants, mutants, deletions, substitutions,insertions, fusions and the like.

A FGF-9 polypeptide or a nucleic acid encoding a FGF-9 polypeptide maybe mutated or changed or derivatised in any manner desired (for example,any number or combination of deletions, insertions, or substitutions) toproduce a corresponding variant. Use of such variants in controllingangiogenesis is contemplated, and such a variant nucleic acid or variantpolypeptide may be mutated or changed or derivatised any manner incomparison to a naturally occurring nucleic acid or polypeptidesequence, respectively, provided that the angiogenic activity ismaintained. Similarly, nucleic acids or polypeptides having varyingdegrees of sequence identity to a corresponding naturally occurringnucleic acid or polypeptide sequence may be tolerated withouteliminating an angiogenic activity. For example, a composition maycomprise an FGF-9 polypeptide having a sequence that is identical to anaturally-occurring form of the FGF-9 polypeptide or a variant thereofthat has a sequence that is at least 80% identical to anaturally-occurring form of the FGF-9 polypeptide. As another example, acomposition may comprise a nucleic acid molecule having a codingsequence that is identical to a naturally-occurring form of the codingsequence or a variant thereof that has a sequence that is at least 70%identical to a naturally-occurring form of the coding sequence.Determination of sequence identity of proteins and nucleic acids bycomputer based methods, as well as nucleic acid hybridization techniquesusing high stringency conditions for determining or identifying nucleicacid sequences that share high (eg., at least 70%) sequence identity arewell known to the skilled person.

Stringency of hybridization reactions is readily determinable by one ofordinary skill in the art, and generally is an empirical calculationdependent upon probe length, washing temperature, and saltconcentration. In general, longer probes require higher temperatures forproper annealing, while shorter probes need lower temperatures.Hybridization generally depends on the ability of denatured DNA toreanneal when complementary strands are present in an environment belowtheir melting temperature. The higher the degree of sequence identitybetween the probe and hybridizable sequence, the higher the relativetemperature which can be used. High stringency conditions may beidentified by those that: (1) employ low ionic strength and hightemperature for washing, for example 0.015 M sodium chloride/0.0015 Msodium citrate/0.1% sodium dodecyl sulfate at 50° C.; (2) employ duringhybridization a denaturing agent, such as formamide, for example, 50%(v/v) formamide with 0.1% bovine serum albumin/0.1% Ficoll/0.1%polyvinylpyrrolidone/50 mM sodium phosphate buffer at pH 6.5 with 750 mMsodium chloride, 75 mM sodium citrate at 42° C.; or (3) employ 50%formamide, 5×SSC (0.75 M NaCl, 0.075 M sodium citrate), 50 mM sodiumphosphate (pH 6.8), 0.1% sodium pyrophosphate, 5×Denhardt's solution,sonicated salmon sperm DNA (50 μg/m)), 0.1% SDS, and 10% dextran sulfateat 42° C., with washes at 42° C. in 0.2×SSC (sodium chloride/sodiumcitrate) and 50% formamide at 55° C., followed by a high-stringency washconsisting of 0.1×SSC containing EDTA 55° C. Hybridization and washtimes should be sufficient for achieving equilibrium.

Percent (%) sequence identity of amino acid or nucleic acid sequenceswith respect to FGF-9 polypeptides and nucleic acid sequences encodingFGF-9 polypeptides is the percentage of residues in a candidate sequencethat are identical with the FGF-9 polypeptide amino acid sequence or theFGF-9 polypeptide-encoding nucleic acid sequence, as the case may be,after aligning the sequences and introducing gaps, if necessary, toachieve the maximum percent sequence identity. Alignment for purposes ofdetermining percent amino acid sequence identity or percent nucleic acidsequence identity can be achieved in various ways that are within theskill in the art, for instance, using publicly available computersoftware such as BLAST, BLAST-2, ALIGN, ALIGN-2 or Megalign (DNASTAR)software. Those skilled in the art can determine appropriate parametersfor measuring alignment, including any algorithms needed to achievemaximal alignment over a desired length of sequence, for example, atleast 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160,170, 180, 190, or 200 residues or even the full-length of the sequencesbeing compared.

When considering a FGF-9 polypeptide or variant thereof, the variantFGF-9 polypeptide will typically have an amino acid sequence that is atleast 80, 82, 84, 86, 88, 90, 92, 94, 96, or 98 percent identical to thecorresponding FGF-9 polypeptide.

When considering a nucleic acid sequence encoding a FGF-9 polypeptide orvariant thereof, the variant nucleic acid sequence will typically be atleast 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, or 98percent identical to the corresponding nucleic acid encoding the FGF-9polypeptide.

Techniques and strategies for producing variants are well known in theart. In one example, with regard to polypeptides, a FGF-9 polypeptidemay be modified in vivo or in vitro by, glycosylation, amidation,phosphorylation, carboxylation, truncation, fragmentation, substitution,and the like without eliminating angiogenic activity. In anotherexample, with regard to nucleic acids, substitution mutations can bemade in a nucleic acid encoding a FGF-9 polypeptide such that aparticular codon is changed to a codon which codes for a different aminoacid. A substitution mutation of this sort can be made to change anamino acid in the resulting protein in a non-conservative manner (i.e.,by changing the codon from an amino acid belonging to a grouping ofamino acids having a particular size or characteristic to an amino acidbelonging to another grouping) or in a conservative manner (i.e. bychanging the codon from an amino acid belonging to a grouping of aminoacids having a particular size or characteristic to an amino acidbelonging to the same grouping). Such a conservative change generallyleads to less change in the structure and function of the resultingprotein. A non-conservative change is more likely to alter thestructure, activity or function of the resulting protein. Groupings ofamino acids are known to the skilled person. For example, the nonpolar(hydrophobic) amino acids include alanine, leucine, isoleucine, valine,proline, phenylalanine, tryptophan and methionine. Amino acidscontaining aromatic ring structures are phenylalanine, tryptophan, andtyrosine. The polar neutral amino acids include glycine, serine,threonine, cysteine, tyrosine, asparagine, and glutamine. The positivelycharges (basic) amino acids include arginine, lysine and histidine. Thenegatively charged (acidic) amino acids include aspartic acid andglutamic acid. Any number of such substitutions or any other type ofalteration (e.g., deletion or insertion) or modification may betolerated provided that the angiogenic effect is not eliminated.

Recombinant cells, comprising a FGF-9 polypeptide or a nucleic acidsequence that encodes a FGF-9 polypeptide may be used for controllingangiogenesis. Recombinant cell types may include any cell type that iscompatible with the physiology of an intended subject for therapeuticangiogenesis or for the application of generating in vitro models ofangiogenesis, vasculogenesis, or any other in vitro model employingintact and stabilized blood vessels.

A cell may be altered or modified to comprise a nucleic acid sequencethat does not naturally occur in the cell, and as such the cell will beconsidered recombinant. In other examples, a cell may be altered ormodified to comprise an additional copy of a nucleic acid sequence thatnaturally occurs in the cell, and such cells will also be consideredrecombinant. As is understood by one of skill in the art, a nucleic acidencoding a FGF-9 polypeptide may be introduced into a cell using anyknown technique, for example, microinjection, electroporation, viraltransfection, lipofectamine transfection, calcium phosphateprecipitation and the like. In certain non-limiting examples, a stemcell may be modified by introduction of a nucleic acid molecule encodinga FGF-9 polypeptide, and then the modified cells may be administered toa subject. In certain other examples, a nucleic add molecule encoding aFGF-9 polypeptide may be incorporated into an appropriate construct orvehicle, for example a viral construct, and administered to a subjectsuch that the nucleic add molecule encoding the FGF-9 polypeptide isintroduced and expressed in at least a portion of the cells of thesubject.

A nucleic acid encoding a FGF-9 polypeptide may be operably linked tocontrol sequences, typically in the context of a suitable vector. Auseful control sequence may be any nucleic add element that is necessaryor advantageous for expression of the coding sequence of the nucleicacid sequence. Each control sequence may be native or foreign to thenucleic acid sequence encoding the FGF-9 polypeptide. Such controlsequences include, but are not limited to, a leader, a polyadenylationsequence, a propeptide sequence, a promoter, a signal sequence, or atranscription terminator. Alternatives for incorporating controlsequences are readily available to the skilled person. For example, anucleic acid encoding a FGF-9 polypeptide may be under the control of anendogenous upstream promoter, or it may be put under control of aheterologous upstream promoter. Examples of suitable promoters fordirecting the transcription of the modified nucleotide sequence, such asPS4 nucleic acids, in a bacterial host include the promoter of the lacoperon of E. coli, the Streptomyces coelicolor agarase gene dagApromoters, the promoters of the Bacillus licheniformis alpha-amylasegene (amyL), the promoters of the Bacillus stearothermophilus maltogenicamylase gene (amyM), the promoters of the Bacillus amyloliquefaciensalpha-amylase gene (amyQ), the promoters of the Bacillus subtilis xylAand xylB genes, the promoter of the Bacillus subtilis aprE gene and apromoter derived from a Lactococcus sp.-derived promoter including theP170 promoter. When the gene encoding the PS4 variant polypeptide isexpressed in a bacterial species such as E. coli, a suitable promotercan be selected, for example, from a bacteriophage promoter including aT7 promoter and a phage lambda promoter.

For transcription in a fungal species, examples of useful promoters arethose derived from the genes encoding the, Aspergillus oryzae TAKAamylase, Rhizomucor miehei aspartic proteinase, Aspergillus nigerneutral alpha-amylase, A. niger add stable alpha-amylase, A. nigerglucoamylase, Rhizornucar miehei lipase, Asperginus oryzae alkalineprotease, Aspergillus oryzae triose phosphate isomerase or Aspergillusnidulans acetamidase.

Examples of suitable promoters for the expression in a yeast speciesinclude but are not limited to the Gal 1 and Gal 10 promoters ofSaccharomyces cerevisiae and the Pichia pastoris AOX1 or AOX2 promoters.

Still further suitable promoters are available to the skilled person,for example, cytomegalovirus, Rous Sarcoma Virus, synthetic pox viralpromoter, pox synthetic late promoter 1, pox synthetic late promoter 2early promoter 2, pox 011 promoter, pox 141 promoter, pox 13L promoter;pox 12L promoter, pox 11L promoter, pox DIOR promoter, PRV gX, HSV-1alpha 4, chicken beta-actin promoter, HCMV immediate early, MDV gA, MDVgB, MDV gD, MDV gB, BHV-1.1 VP8 and ILT gD and internal ribosomal entrysite promoter.

A suitable vector may be any vector (for example, a plasmid or virus)which can incorporate a nucleic acid sequence encoding a FGF-9polypeptide and any desired control sequences and can bring about theexpression of the nucleic acid sequence. The choice of the vector willtypically depend on the compatibility of the vector with a host cellinto which the vector is to be introduced. In certain examples, thevector may exist as an extrachromosomal entity, with replication beingindependent of chromosomal replication, for example, a plasmid, anextrachromosomal element, a minichromosome, or an artificial chromosome.In other examples, the vector may be one which, when introduced into thehost cell, is integrated into the genome and replicated together withthe chromosome(s) into which it has been integrated. Still otherexamples of vectors and techniques for manipulating vectors will beknown and apparent to the skilled person.

Recombinant cells may comprise a FGF-9 polypeptide or a nucleic acidsequence encoding a FGF-9 polypeptide, either singly or in combination,with other desired polypeptide or nucleic acid molecules, respectively,for example to optimize or enhance efficacy. Furthermore, a nucleic addsequence may be mutated or altered prior to introduction into the cellsas desired, for example for codon optimization for expression in aparticular cell type. In addition, a nucleic acid sequence may bealtered to encoded a fusion of a FGF-9 polypeptide with one or moreother polypeptide as desired in an application, for example fusion witha targeting polypeptide or a carrier polypeptide.

The skilled person will recognize that variants described herein withrespect FGF-9 molecules and cells comprising FGF-9 molecules can applyequally to other polypeptides, nucleic acid molecules, and cells thatare used in combination with FGF-9 molecules and cells comprising FGF-9molecules. In certain examples, angiogenic polypeptides, nucleic acidmolecules encoding angiogenic polypeptides or cells producing angiogenicpolypeptides may be used in combination with FGF-9 molecules or cellsproducing FGF-9 molecules. Such angiogenic polypeptides include othermembers of the fibroblast growth factor (FGF) family, the vascularendothelial growth factor (VEGF) family, the platelet-derived growthfactor (PDGF) family, or the insulin-like growth factor (IGF) family. Incertain examples, an FGF-9 molecule is used in combination with FGF2. Incertain examples other polypeptides, nucleic acid molecules, or cellsthat are used in combination with FGF-9 molecules and cells comprisingFGF-9 molecules may include appropriate extracellular matrix proteins tocomprise a 3-dimensional structure in vitro or a biomaterial fortherapeutic purposes. Such extracellular matrix proteins may include butare not limited to naturally occurring molecules such as collagen,fibrin, and proteoglycans.

As is understood by the skilled person, administration of polypeptides,nucleic acid molecules, or cells can be done in a variety of manners andcombinations thereof. For example, administration may be doneintramuscularly, subcutaneously, intravenously, intranasally,intradermaly, intrabursally, in ova, ocularly, orally, intra-tracheallyor intra-bronchially, as well as combinations of such modalities. Thedose may vary with the size of the intended subject. Methods ofadministration are known to the skilled person, for example, U.S. Pat.Nos. 5,693,622; 5,589,466; 5,580,859; and 5,566,064. The amounts ofpolypeptide, nucleic acid sequence, or recombinant cell needed forpreparation of a composition is well understood by one of skill in theart.

The polypeptides, nucleic acids, or recombinant cells as describedherein, may be used in combination with a pharmaceutically acceptablecarrier for preparation of a composition for controlling angiogenesis.Pharmaceutically acceptable carriers are well known to those skilled inthe art and include but are not limited to proteins, sugars, and thelike. One example of such a suitable carrier is a physiologicallybalanced culture medium containing one or more stabilizing agents suchas hydrolyzed proteins, lactose, and the like. Another example of anacceptable carrier is 0.01-0.1M, and preferably 0.05M, phosphate bufferor 0.8% saline. Acceptable carriers may be aqueous or non-aqueoussolutions, suspensions, and emulsions. Examples of non-aqueous solventsare propylene glycol, polyethylene glycol, vegetable oils such as oliveoil, and injectable organic esters such as ethyl oleate. Examples ofaqueous carriers are water, alcoholic/aqueous solutions, emulsions orsuspensions, including saline and buffered media. Preservatives andother additives for pharmaceutical compositions are also well known tothe skilled person, for example antimicrobials, antioxidants, chelatingagents, inert gases, organic acids and the like. Another example of sucha suitable carrier is a biomaterial comprising natural or syntheticextracellular matrix material.

The phrases “parenteral administration” and “administered parenterally”are art-recognized terms, and include modes of administration other thanenteral and topical administration, such as injections, and include,without limitation, intravenous, intramuscular, intrapleural,intravascular, intrapericardial, intraarterial, intrathecal,intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal,transtracheal, subcutaneous, subcuticular, intra-articular, subcapsular,subarachnoid, intraspinal and intrasternal injection and infusion.

The term “treating” is an art-recognized term which includes curing aswell as ameliorating at least one symptom of any condition or disease.

The phrase “pharmaceutically acceptable” is art-recognized. In certainembodiments, the term includes compositions, polymers and othermaterials and/or dosage forms which are, within the scope of soundmedical judgment, suitable for use in contact with the tissues of humanbeings and animals without excessive toxicity, irritation, allergicresponse, or other problem or complication, commensurate with areasonable benefit/risk ratio.

The phrase “pharmaceutically acceptable carrier” is art-recognized, andincludes, for example, pharmaceutically acceptable materials,compositions or vehicles, such as a liquid or solid filler, diluent,excipient, solvent or encapsulating material, involved in carrying ortransporting any subject composition from one organ, or portion of thebody, to another organ, or portion of the body. Each carrier must be“acceptable” in the sense of being compatible with the other ingredientsof a subject composition and not injurious to the patient. In certainembodiments, a pharmaceutically acceptable carrier is non-pyrogenic.Some examples of materials which may serve as pharmaceuticallyacceptable carriers include: (1) sugars, such as lactose, glucose andsucrose; (2) starches, such as corn starch and potato starch; (3)cellulose, and its derivatives, such as sodium carboxymethyl cellulose,ethyl cellulose and cellulose acetate; (4) powdered tragacanth; (5)malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter andsuppository waxes; (9) oils, such as peanut oil, cottonseed oil,sunflower oil, sesame oil, olive oil, corn oil and soybean oil; (10)glycols, such as propylene glycol; (11) polyols, such as glycerin,sorbitol, mannitol and polyethylene glycol; (12) esters, such as ethyloleate and ethyl laurate; (13) agar; (14) buffering agents, such asmagnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16)pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19)ethyl alcohol; (20) phosphate buffer solutions; and (21) other non-toxiccompatible substances employed in pharmaceutical formulations.

The term “pharmaceutically acceptable salts” is art-recognized, andincludes relatively non-toxic, inorganic and organic acid addition saltsof compositions of the present invention, including without limitation,therapeutic agents, excipients, other materials and the like. Examplesof pharmaceutically acceptable salts include those derived from mineralacids, such as hydrochloric acid and sulfuric acid, and those derivedfrom organic acids, such as ethanesulfonic acid, benzenesulfonic acid,p-toluenesulfonic acid, and the like. Examples of suitable inorganicbases for the formation of salts include the hydroxides, carbonates, andbicarbonates of ammonia, sodium, lithium, potassium, calcium, magnesium,aluminum, zinc and the like. Salts may also be formed with suitableorganic bases, including those that are non-toxic and strong enough toform such salts. For purposes of illustration, the class of such organicbases may include mono-, di-, and trialkylamines, such as methylamine,dimethylamine, and triethylamine; mono-, di- or trihydroxyalkylaminessuch as mono-, di-, and triethanolamine; amino acids, such as arginineand lysine; guanidine; N-methylglucosamine; N-methylglucamine;L-glutamine; N-methylpiperazine; morpholine; ethylenediamine;N-benzylphenethylamine; (trihydroxymethyl)aminoethane; and the like.See, for example, J. Pharm. Sci., 66:1-19 (1977).

A “patient,” “subject,” or “host” to be treated by the subject methodmay mean either a human or non-human animal, such as primates, mammals,and vertebrates.

The term “prophylactic or therapeutic” treatment is art-recognized andincludes administration to the host of one or more of the subjectcompositions. If it is administered prior to clinical manifestation ofthe unwanted condition (e.g., disease or other unwanted state of thehost animal) then the treatment is prophylactic, i.e., it protects thehost against developing the unwanted condition, whereas if it isadministered after manifestation of the unwanted condition, thetreatment is therapeutic (i.e., it is intended to diminish, ameliorate,or stabilize the existing unwanted condition or side effects thereof).

The phrases “systemic administration,” “administered systemically,”“peripheral administration” and “administered peripherally” areart-recognized, and include the administration of a subject compositionor other material other than directly into the central nervous system,e.g., by subcutaneous administration, such that it enters the patient'ssystem and, thus, is subject to metabolism and other like processes.

The phrase “therapeutically effective amount” is an art-recognized term.In certain embodiments, the term refers to an amount of the therapeuticagent that, when used alone or in combination with a suitable matrix ofthe present invention, produces some desired effect at a reasonablebenefit/risk ratio applicable to any medical treatment. In certainembodiments, the term refers to that amount necessary or sufficient tocontrol the formation and/or stabilization of blood vessels. Theeffective amount may vary depending on such factors as the disease orcondition being treated, the particular targeted constructs beingadministered, the size of the subject or the severity of the disease orcondition. One of ordinary skill in the art may empirically determinethe effective amount of a particular compound without necessitatingundue experimentation. The exact formulation, route of administrationand dosage for the composition and pharmaceutical compositions disclosedherein can be chosen by the individual physician in view of thepatient's condition. (See. e.g., Fingi et al. 1975, in “ThePharmacological Basis of Therapeutics”, Chapter 1, which is herebyincorporated herein by reference in its entirety). The dosage may be asingle one or a series of two or more given in the course of one or moredays, as is needed by the patient. Where no human dosage is established,a suitable human dosage can be inferred from ED₅₀ or ID₅₀ values, orother appropriate values derived from in vitro or in vivo studies, asqualified by toxicity studies and efficacy studies in animals. Dosageintervals can also be determined using MEC value. Compositions should beadministered using a regimen which maintains plasma levels above the MECfor approximately 10% and approximately 90% of the time, preferablybetween approximately 30% and approximately 90%, and most preferablybetween approximately 50% and approximately 90%.

The amount of FGF-9 composition of the invention required foradministration to provide a therapeutic effect varies as is understoodby one of skill in the art and may vary depending on the embodiment ofthe invention; used in vitro, in vivo systemically, in vivo locally; inconjunction with a biomaterial; in an in vivo extended release format.Therefore, in some aspects the dosage may be from about 0.1 ng/ml to 100ng/ml. In other aspects the dosage may be up to about 500 ng/ml. Instill other aspects the amount may range up to about 1 mg/kg to about100 mg/kg. It is understood by those of skill in the art that the amountof FGF-9 composition of the invention may be selected from any sub-rangeof the therapeutic dosages described herein: up to 0.01 ng/ml, up to 500ng/ml. Dosages expressed by weight may also cover up to about 1 mg/kg toabout 1000 mg/kg range, such as for example but not limited to; 1mg/kg-500 mg/kg; 1 mg/kg-250 mg/kg; 1 mg/kg-200 mg/kg; 1 mg/kg-150mg/kg; 1 mg/kg-75 mg/kg; 1 mg/kg-50 mg/kg; and 1 mg/kg-25 mg/kg and anysub-ranges of any of these ranges. Again, it is also possible that theamount may be greater than 1000 mg/kg and in some aspects less than 1mg/kg.

In one embodiment, the pharmaceutical FGF-9 compositions provided hereinmay be formulated as controlled-release compositions, i.e. compositionsin which the FGF-9 and other angiogenic polypeptide(s) is released overperiod of time after administration. Controlled- or sustained-releasecompositions include formulation in lipophilic depots (e.g. fatty acids,waxes, oils). In another embodiment, the composition is animmediate-release composition, i.e. a composition in which all of theFGF-9 and other angiogenic polypeptide(s) is released immediately afteradministration.

In yet another embodiment, the pharmaceutical compositions of theinvention can be delivered in a controlled release system. For example,the FGF-9 composition comprising angiogenic polypeptide(s) may beadministered using intravenous infusion, an implantable osmotic pump, atransdermal patch, liposomes, or other modes of administration. In oneembodiment, a pump may be used (see Langer, supra; Sefton, CRC Crit.Ref. Biomed. Eng. 14:201 (1987); Buchwald et al., Surgery 88:507 (1980);Saudek et al., N. Eng1.1. Med. 321:574 (1989). In another embodiment,polymeric materials can be used. In yet another embodiment, a controlledrelease system can be placed in proximity to the therapeutic target,i.e., the brain, thus requiring only a fraction of the systemic dose(see, e.g., Goodson, in Medical Applications of Controlled Release,supra, vol. 2, pp. 115-138 (1984). Other controlled-release systems arediscussed in the review by Langer (Science 249:1527-1533 (1990). Thecompositions of the invention may also include incorporation of FGF-9active into or onto particulate preparations of polymeric compounds suchas polylactic add, polyglycolic add, hydrogels, etc, or onto liposomes,microemulsions, micelles, unilamellar or multilamellar vesicles,erythrocyte ghosts, or spheroplasts.) Such compositions will influencethe physical state, solubility, stability, rate of in vivo release, andrate of in vivo clearance.

Also comprehended by the invention are particulate compositions coatedwith polymers (e.g. poloxamers or poloxamines) and the compound coupledto antibodies directed against tissue-specific receptors, ligands orantigens or coupled to ligands of tissue-specific receptors.

Also embodied by the invention are the FGF-9 compounds modified by thecovalent attachment of water-soluble polymers such as polyethyleneglycol, copolymers of polyethylene glycol and polypropylene glycol,carboxymethyl cellulose, dextran, polyvinyl alcohol,polyvinylpyrrolidone or polyproline. The modified compounds are known toexhibit substantially longer half-lives in blood following intravenousinjection than do the corresponding unmodified compounds (Abuchowski etal., 1981; Newmark et al., 1982; and Katre et al., 1987). Suchmodifications may also increase the compound's solubility in aqueoussolution, eliminate aggregation, enhance the physical and chemicalstability of the compound, and greatly reduce the immunogenicity andreactivity of the compound. As a result, the desired in vivo biologicalactivity may be achieved by the administration of such polymer-compoundabducts less frequently or in lower doses than with the unmodifiedcompound.

In a non-limiting embodiment, a localized medical device orbiodegradable implant may be used to includes the functionality oftime-course release of the compositions of the invention. The medicaldevice may be composed of a solid casing with internal gel-like fluidcontaining the FGF-9 compositions of the invention. The gel-like fluidmay be a cryoprecipitate, an administration matrix, or a composition ofvarious polymers suitable for the sustained release of the composition.The biodegradable implant contains a biodegradable delivery means, orcarrier, as well as the FGF-9 compositions of the invention. The carriermay be chosen so as to remain within the implanted site for a prolongedperiod and slowly release the angiogenic factors contained therein tothe surrounding environment. This mode of delivery allows the FGF-9compositions of the invention to remain in therapeutically effectiveamounts within the site for a prolonged period.

The above disclosure generally describes the present invention. A morecomplete understanding can be obtained by reference to the followingspecific Examples. These Examples are described solely for purposes ofillustration and are not intended to limit the scope of the invention.Changes in form and substitution of equivalents are contemplated ascircumstances may suggest or render expedient. Although specific termshave been employed herein, such terms are intended in a descriptivesense and not for purposes of limitation.

EXAMPLES Example 1 FGF-9 Variants

FGF-9 sequences and variants thereof may be derived from variousnaturally occurring sources. For example, FIG. 1 shows nucleic acidsequences encoding Human, Mouse and Rat FGF-9 retrieved from GenBank. Asanother example, FIG. 2 shows a multiple sequence alignment of Human,Mouse, Rat, and Pig FGF-9 amino acid sequences. Species specific aminoacid sequences of FGF-9 retrieved from GenBank were aligned usingJalView 2.3. A high degree of conservation in the amino acid sequencecan be observed.

Variants of the FGF-9 sequences shown in FIG. 1 or 2 can be producedusing known methods such as those described in Sambrook J et al. 2000.Molecular Cloning: A Laboratory Manual (Third Edition). Variants may betested for the ability of wrapping and/or stabilizing a blood vessel.

Example 2 High Throughout Screening for the Factors Secreted by SMCs asthey Acquire Specialized Functions

Human SMCs were subjected to serum deprivation for 8 days. This processconverts SMCs to a state whereby they migrate in a specialized pattern.SMCs acquiring this specialized phenotype typically possess the abilityof wrapping and stabilizing blood vessels. RNA harvested at days 0 and 8was subsequently subjected to high density microarray analysis usingAffymetrix U133 arrays. Three biological replicates were performed.

Analysis of microarray data revealed that of 1087 secreted factorsexpressed by SMCs only 27 were statistically upregulated as SMCsacquired the specialized phenotype. Of the 27 upregulated genes, FGF-9was the most upregulated. The upregulation of FGF-9 was confirmed at theprotein level as shown in FIG. 3.

Example 3 FGF-9 is Upregulated as SMCs Acquired Specialized Functions

Human SMCs were subjected to serum deprivation for 8 days. This processconverts SMCs to a state whereby they migrate in a specialized pattern.SMCs acquiring this specialized phenotype typically possess the abilityof wrapping and stabilizing blood vessels. RNA harvested at days 0 and 8was subsequently subjected to high density microarray analysis.

As shown in FIG. 4 expression of FGF-3, 6, 8, 10, 13, 17, 19, 20, 22 andFGFR-4 was not detected. Expression of FGF-7, 11, 12, 14, 18 and FGFR-1,2, and 3 was detected but did not change in response to serumwithdrawal. FGF-1, 2 and 5 were downregulated in response to serumwithdrawal while FGF-9 was upregulated as SMCs acquired the specializedphenotype.

Example 4 FGF-9 does not Initiate the Angiogenic Process inSubcutaneously Implanted Matrigel in Mice

Matrigel plugs were mixed with either 500 ng/mL FGF-9, 500 ng/mL FGF-2or 500 ng/ml. FGF-2 and 20 ng/mL FGF-9 and subcutaneously injected into3 month old C57/Bl6 mice. Mice were sacrificed and matrigel plugs wereharvested 8 days after implantation and immunostained for CD31 (brown),to identify endothelial cell-lined microvessels

FIG. 5 shows the results of this experiment. FGF-9 alone did not induceangiogenesis as indicated by an absence of CD31 immunoreactivity insidethe matrigel (FIG. 5A). FGF-2 (FIG. 5B) and FGF-2+FGF-9 (FIG. 5C) bothinduce angiogenesis in the matrigel as indicated by CD31immunoreactivity (brown).

CD31-positive microvessels immunostained in FIGS. 5B and 5C arequantified. Graphical representation of the area of CD31-positivemicrovessels as shown in FIG. 5D indicates that equivalent levels ofangiogenesis occur in matrigel plugs containing FGF-2 (FIG. 5B) andFGF-2 FGF-9 (FIG. 5C). 5E FGF-9 stimulates the formation of perfusablevessels. Mice bearing matrigel plugs containing FGF-2 or FGF-2 FGF-9 for7 days were sacrificed and perfused with microfil and subjected toThree-dimensional (3D) micro-computed tomography (micro CT). The graphdepicts the depth to which perfusable vessels penetrated the matrigelplug and demonstrates that vessels formed in matrigel containingFGF-2+FGF-9 were more functional and had a higher degree of perfusioncompared to FGF-2 alone.

Example 5 FGF-9 Stimulates Recruitment of SM α-Actin Expressing MuralCells to Nascent Microvessels During Angiogenesis

Photomicrographs of 8 μm-thick sections of Matrigel plugs harvested 8days after implantation into C57/Bl6 mice and immunostained for CD31(brown) and smooth muscle α-actin (red) and quantification of thepercentage of microvessels supported by smooth muscle (5M) α-actinpositive cells.

FGF-9 induced the recruitment of smooth muscle α-actin positive cellsaround CD31-positive microvessels to a substantially greater extent thanFGF-2 alone. Quantification of investment of nascent blood vessels by SMα-actin positive cells, as shown in the graph in FIG. 6, confirmed thatFGF-9 stimulated the recruitment of smooth muscle around microvessels toa much greater extent than FGF-2 alone (83±7.7% vs. 37±5.4% P<0.05).

Example 6 FGF-9 Stimulates SM α-Actin Expressing Mural Recruitment AlongContinuous Lengths of Blood Vessels

Photomicrographs of Matrigel plugs harvested 8 days after implantation,cut into 200 μm thick-sections and immunostained for CD31 (left panel)and SM α-actin (central panel) and quantitation of SM α-actin coverageof CD31-positive vessels.

FGF-9 induced SM α-actin positive cells to associate along large lengthof nascent microvessels. Quantification of SM α-actin positive cellcoverage of CD31 nascent blood vessels, as shown in the graph in FIG. 7,revealed that FGF-9 induced significantly more coverage compared toFGF-2 (45.4±53% vs. 7.2±1.8% P<0.05).

Example 7 FGF-9 Stimulates Circumferential Wrapping of Blood Vessels bySM α-Actin Expressing Mural Cells

Confocal microscopy of FGF-2±FGF-9 matrigel plugs harvested 8 days afterimplantation. Sequential images, 1 μm thick, along the z-axis werecollected to obtain 90 μm thick z-stack depicting the vessel.

FIG. 8A shows orthogonal views of CD31-positive endothelial cells (leftpanel) and SM α-actin mural cells (central panel). FIG. 88 shows a threedimensional reconstruction of a 90 μm thick z-stack composed of 1 μmthick images.

The orthogonal views depict tight association between endothelial andsupporting SM α-actin mural cells along the length of the vessel. Thethree dimensional reconstruction of the entire z-stack of this vesselsillustrated that the actin positive mural cells circumferentiallywrapped around the blood vessel, reminiscent of the organization foundin vivo. This highlights the intimate and structurally cohesiveassociation of SM α-actin expressing mural cells with blood vesselsimplying physiologic stabilization.

Example 8 FGF-9-Modified Microvessels are Responsive to VasoactiveStimuli and can Vasodilate and Vasoconstrict

14 days after matrigel injection mice were anesthetized, the skinoverlying a matrigel was surgically removed and a catheter to deliverdrugs was sutured in the region of the plug. FITC-labeled dextran wasinjected via tail vein and the diameter of vessels in the matrigel plugwas visualized using an inverted fluorescent microscope. Doses ofvasoconstrictors indicated in FIG. 9 were applied and images of vesselswere acquired over 5 minutes.

Representative tracings from separate mice, of the change in vesseldiameter over time in response to phenylephrine (PE) and KCI are shownin FIG. 9. FGF-9-modified microvessels exhibited larger constrictions inresponse to PE and KCI compared to FGF-2 induced microvessels.

The tracings in FIG. 9B depict the change in vessel diameter in responseto phenylephrine and KCI treatment. KCI will depolarize SMCs and resultin receptor independent constriction if they are present on the bloodvessels. FGF-2 induced vessels exhibit mild if any response tovasoconstrictors while the diameter of FGF-9 vessels is reduced by up to65% of their initial diameter.

In separate experiments, doses of the vasoconstrictor PE followed by thevasodilator were applied to the blood vessels in matrigel plugs.Micrographs in C demonstrates that blood vessels in FGF-2 FGF-9containing matrigel plugs constricted in response to PE and dilated inresponse to SNP.

Example 9 FGF-9-Stimulated Wrapping is Dependent on the Upregulation ofPDGFR-β

Mouse dermal fibroblasts were stimulated with the doses of FGF-2 orFGF-9, indicated in FIG. 11A, for 24 h and then harvested. Cellularprotein was separated by SDS-PAGE and the abundance of PDGFR-β wasassessed by western blot analysis. As shown in FIG. 11A, FGF-9 inducedthe upregulation of PDGFR-β protein in mouse dermal fibroblasts.

Matrigel plugs containing either FGF-2 or FGF-2 FGF-9 were harvested 8days after implantation and immunostained for PDGFR-β. As shown in FIG.11B, PDGFR-β expression was markedly increased in matrigel plugscontaining FGF-2+FGF-9 compared to FGF-2 alone.

Matrigel plugs containing either FGF-2 or FGF-2 FGF-9 in the presence ofa PDGFR-β blocking antibody were harvested 8 days after implantation.The association of SM α-actin positive mural cells at blood vessels wasassessed by immunostaining for CD31 and SM α-actin. The graph in FIG.11C shows that blockade of PDGFR-β attenuates FGF-9-mediated recruitmentof SM α-actin positive mural cells to nascent blood vessels compared tocontrol antibody (18±4.4% vs. 87±4.3% p<0.05).

Example 10 FGF-9 Upregulates SMC Recruitment Proteins In Vitro and InVivo

A number of factors related to angiogenesis were screened in culture inan effort to identify mediators of FGF-9 effects. Several factors,including Vegf and TGF-beta1 were unaffected by FGF-9 treatment oroverexpression. In contrast PDGFR-β, a mediator of SMC homing toendothelial cells was upregulated by FGF-9 treatment and overexpressionin human smooth muscle cells and mouse dermal fibroblasts (FIG. 11A-C).

Also components of Sonic Hedgehog signaling, which are required forformation of arteries in zebrafish were also upregulated at the mRNAlevel. The upregulation of PDGFR-β by FGF-9 during angiogenesis wasconfirmed in vivo by immunohistochemistry (FIG. 11B). The effect of aPDGFR-β blocking antibody on SMC recruitment to nascent vessels in vivowas also tested.

Example 11 2- and 3-Dimensional Vasculogenesis Assay

Human SMCs were treated with increasing doses of FGF-9 for 24 hr. Humanumbilical endothelial cells expressing eGFP (green fluorescent protein)were plated onto growth factor-reduced matrigel coated dishes at adensity of 1.5×10⁴ cells/cm². After 4 hr human smooth muscle cellsexpressing mRFP (red fluorescent protein) were added at a density of1.5×10⁴ cells/cm² and the migration of SMCs to endothelial tubules wastracked microscopically for 24 h optionally in the presence of 100 ng/mlof FGF-9. Fluorescence photomicrographs depict the association of mRFPexpressing SMCs with eGFP expressing endothelial tubules 10 h afteraddition of SMCs (FIG. 12).

Subsequently, endothelial cells and human SMCs will be co-cultured onmatrigel, or within a matrigel or equivalent matrix using methodologieswell known to someone skilled in the art (for example as described inScaffolding in Tissue Engineering (eds. Ma, P. X. and Eliseeff, J), 2005CRC Press, Boca Raton, Fla.), to produce two dimensional and3-dimensional cultures respectively. The formation, activity, andstabilization of blood vessels in the cultures will be assayed.Supplemented in such cultures will be variations of and combinations ofoptimized concentrations of FGF2 and FGF9. Over time, the assembly ofblood vessels and the extent of vasculogenesis will be tracked by timelapse microscopy, and properties evaluated by confocal microscopy. Thereactivity of such vessels will be evaluated by methods alreadydescribed herein.

Example 12 FGF-9 Stabilizes the Neovasculature and the VesselStabilization is Persistent Over Time

A Photomicrographs of matrigel plugs (FIG. 12) harvested 1 year afterimplantation and immunostained for CD31 (brown) 1213 Quantification ofangiogenesis assessed as the area containing CD31 positive microvessels.FGF-2+FGF-9-containing matrigel plugs had significantly more vessels 1year after implantation especially vessels with a diameter greater than15 μM.

Example 13 FGF-9 Stimulates the Recruitment to the Neovasculature

A. Photomicrographs (FIG. 13) of matrigel plugs containing either FGF-2or FGF-2+FGF-9 harvested 28 days after implantation and immunostainedfor the neurofilament protein marker NF-200 to detect the presence ofblood vessel-associated nerves. B. The graph depicts the percentage ofnerved-associated blood vessels at 14 and 28 days after implantation.

Example 14 Stimulated Wrapping is Dependent on the Upregulation ofPDGFR-β

A. RT-PCR of human aortic SMCs (FIG. 14) stimulated with increasingconcentrations of recombinant FGF-9 for 24 h. A number of genes involvedin angiogenesis were assessed. With only PDGFR-β being upregulated B,RT-PCR of human aortic SMCs overexpressing cDNA encoding GFP or FGF-9.C, Western Blots of C57/Bl6 dermal fibroblasts treated with either FGF-2or FGF-9 for 24 h.

Mouse dermal fibroblasts were stimulated with the doses of FGF-2 orFGF-9, indicated in FIG. 15C, for 24 hand then harvested. Cellularprotein was separated by SDS-PAGE and the abundance of PDGFR-β wasassessed by western blot analysis. As shown in FIG. 14B, in contrast toFGF-2, FGF-9 induced the upregulation of PDGFR-β protein in mouse dermalfibroblasts.

Photomicrographs of Matrigel plugs containing FGF-2 FGF-9 with eithercontrol IgG or PDGFR-β blocking antibody double immunolabeled for CD31(brown) and sm α-actin (red) harvested 8 days after implantation. Thepresence of PDGFR-β blocking antibody attenuated the FGF-9 inducedrecruitment of sm α-actin positive cells to new blood vessels. EQuantitation of SM α-actin coverage of CD31-positive vessels in micebearing FGF-2 or FGF-2 FGF-9 with either control IgG or PDGFR-β blockingantibody. The graph in FIG. 11E shows that blockade of PDGFR-βattenuates FGF-9-mediated recruitment of SM α-actin positive mural cellsto nascent blood vessels compared to control antibody (18±4.4% vs.87±4.3% p<0.05).

Example 15 FGF-9-Mediated PDGFR-β Upregulation and Vessel MaturationRequires Sonic Hedgehog Signaling

FIG. 15A. RT-PCR of human aortic SMCs stimulated with increasingconcentrations of recombinant FGF-9 for 24 h. 15B, RT-PCR of humanaortic SMCs overexpressing cDNA encoding GFP or FGF-9. 15C, WesternBlots of C57/Bl6 dermal fibroblasts pretreated with either DMSO or 500nM cycloparnine and subsequently stimulated with vehicle or FGF-9 for 24hr, 15D. Photomicrographs of FGF-2 and FGF-9 containing matrigel plugswith either DMSO or cyclopamine double immunolabeled for CD31 (brown)and sm α-actin (red). E Quantitation of SM α-actin coverage ofCD31-positive vessels representative of 6 mice bearing FGF-2 orFGF-2+FGF-9 with either vehicle or 500 nM cyclopamine (79±4 vs 38±4.8,p<0.05).

Example 16 In Vitro Direct Effects on SMCs in Culture

FIG. 16A. Lysates of SMCs expressing either GFP or FGF-9 were subjectedto Western blot analysis to assess levels of smooth muscle cell markers.SMCs expressing FGF-9 exhibited a more primitive and plastic phenotypecompared to GFP expressing cultures as indicates by decreased levels ofsmooth muscle α-actin and calponin. 16B. WPCs expressing either GFP orFGF-9 were stained with Annexin to detect apoptotic cells and subjectedto flow cytometry. Cultures of SMC expressing FGF-9 were less apoptoticas indicated by the smaller proportion of Annexin positive cells. C.SMCs expressing either GFP or FGF-9 were serially cultured and countedto determine their cumulative population doubling and DNA from eachpassage was isolated and subjected to real time PCR analysis to assessthe rate of telomere attrition. The graph shows that cultures of SMCsexpressing FGF-9 experienced a decreased rate of telomere decay comparedto control SMCs.

Example 17 Schematic of Proposal Mechanism of Action for FGF-9 DuringAngiogenesis

FGF-9 signals to a pool of mesenchymal precursors and/or immature stemcells to enhance their survival, prevent senescence. Through either athe same or an unrelated pathway, FGF-9 activates Sonic Hedgehogsignaling to induce the upregulation of the PDGFR-β receptor on thesemesenchymals cells. This increase the competence of this pool of cellsto migrate to the ligand for this receptor, PDGF-bb which is secreted byendothelial cells forming new blood vessels. The recruitment ofmesenchymal cells to blood vessels results in their maturation to SMCcells which are capable of stabilizing the nascent microvasculature andimparting vasoresponsiveness (FIG. 17).

Example 18 Orthotopic Renal Cancer Model of Metastases

An animal model of metastatic cancer was generated. FGF-9 alone, oroptionally in combination with another angiogenic molecule, wasadministered to mice to demonstrate utility in treatment of cancer, itis established that angiogenesis drives the growth of tumors and thatthe blood vessels formed in tumors lack supporting mural cells and areprone to leakage. A negative correlation has been established betweenvessels coverage and metastasis and poor survival in human colorectalcancers. Recent studies have functionally demonstrated that wrapping oftumor blood vessels can limit tumor cell metastasis.

Female Balb/c mice were injected in the subcapsular space of the leftkidney with 5×10⁵ RENCA cells expressing either GFP or FGF-9 suspendedin growth factor reduced matrigel. After 14 days, both kidneys wereexcised and lungs were excised and assessed. FIG. 18A. Photographs ofexcised lungs from Balb/c mice bearing kidney tumors derived from eitherGFP- or FGF-9 expressing RENCA cells. Surface metastases can beidentified as irregular translucent bulges/distentions/protruberance onthe lung surface (arrows) and were more prevalent in GFP-RENCA bearingmice. 18B. Quantitation of kidney weight which indicates that there wasno difference in the size of primary tumors in the left kidney of GFPexpressing RENCA cells compared to FGF-9 expressing RENCA cells (514.9mg±114.6 vs. 536.2 mg±95.4 n=6 GFP vs. FGF-9). 18C. The graph depictsthe average number of surface metastases on the lungs of Balb/c micewith a trend towards a reduction in metastasis in mice bearing tumorsderived from FGF-9 expressing RENCA cells (74±43 vs 2±4.3 n=6)

Example 19 In Vitro Co-Culture

HUVECs expressing EGFP were plated on growth factor reduced matrigel andallowed to adhere for 4 hr before the addition of HITC6 SMCs expressingmRFP, pretreated with the indicated doses of FGF-9 for 16 h, andfluorescent images were subsequently acquired 10 h later, arrowsindicate RFP-positive SMCs aligned along GFP-positive endothelialtubules (FIG. 19). In control conditions few REP-positive cells wereassociated with GFP-positive endothelial tubules while increasingconcentrations of FGF-9 resulted in increasing association of SMCs withendothelial tubules.

Example 20 In Vitro Endothelial Tubules

HUVECs expressing EGFP were plated on growth factor reduced matrigel andallowed to adhere for 4 hr before the addition of HITC6 SMCs expressingmRFP, pretreated with the indicated doses of FGF-9 for 16 h, andfluorescent images were subsequently acquired 10 h later, arrowsindicate REP-positive SMCs aligned along GFP-positive endothelialtubules (FIG. 20). In control conditions few REP-positive cells wereassociated with GFP-positive endothelial tubules while increasingconcentrations of FGF-9 resulted in increasing association of SMCs withendothelial tubules. This together with the results shown in FIGS. 16Band 16C demonstrates better cell survival resulting in vessel formation.

The above-described embodiments are intended to be examples andalterations and modifications may be effected thereto, by those of skillin the art, without departing from the scope of the invention which isdefined by the claims appended hereto

What is claimed is:
 1. A composition for promoting therapeuticangiogenisis in an animal comprising a first isolated nucleic acidmolecule that encodes a FGF-9 polypeptide and a second isolated nucleicacid molecule that encodes an angiogenic polypeptide.
 2. The compositionof claim 1, wherein the PGF-9 polypeptide comprises an amino acidsequence selected from the group consisting of: SEQ ID NO:1, SEQ IDNO:2, SEQ ID NO:3 and SEQ ID NO:4, or a variant thereof.
 3. Thecomposition of claim 2, wherein the FGF 9 polypeptide comprises an aminoacid sequence of SEQ ID NO:1 or a variant thereof that is at least 80%identical to the amino acid sequence of FIG. 1 (SEQ ID NO:1).
 4. Thecomposition of claim 2, wherein the angiogenic polypeptide is selectedfrom the group consisting of FGF2, FGF4, FGF5, PDGF-β FGF-1, VEGF (andall its variant), P1GF, Hedgehog family member (Sonic, Indian andDesert), SDF-1 and IGF.
 5. The composition of claim 2, wherein thevariant comprises an amino acid sequence having at least 80% identitywith the amino acid sequence selected from the group consisting of: SEQID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.
 6. The composition ofclaim 1, wherein the first isolated nucleic acid molecule comprises anucleic acid sequence that hybridizes to the complement of the nucleicacid sequence that encodes an amino acid sequence selected from thegroup consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ IDNO:4, or a variant thereof.
 7. The composition of claim 5, wherein thehybridization occurs under stringent hybridization and wash conditions.8. The composition of any one of claims 1 to 7, wherein the firstisolated nucleic acid molecule is comprised within a vector.
 9. Thecomposition of any one of claims 1 to 7, wherein the first isolatednucleic acid molecule is comprised within a recombinant cell.
 10. Thecomposition of claim 9, wherein the first isolated nucleic acid moleculeis integrated into the chromosome of the recombinant cell.
 11. Thecomposition of claim 9, wherein the first isolated nucleic acid moleculeis extrachromosomal within the recombinant cell.
 12. The composition ofany one of claims 9 to 11, wherein the recombinant cell is a stem cell.13. The composition of any one of claims 1 to 12, wherein the animal isa mammal.
 14. The composition of any one of claims 1 to 12, wherein theanimal is a mammal selected from the group consisting of mouse, pig,dog, rat, and human.
 15. The composition of claim 14, wherein the mammalis a human.
 16. A composition for promoting therapeutic angiogenesis inan animal comprising an isolated FGF-9 polypeptide and one or more otherangiogenic polypeptides.
 17. The composition of claim 16, wherein theFGF-9 polypeptide comprises an amino acid sequence selected from thegroup consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ IDNO:4, or a variant thereof.
 18. The composition of claim 17, wherein theFGF-9 polypeptide comprises an amino acid sequence of SEQ ID NO:1 or avariant thereof that is at least 80% identical to the amino acidsequence of SEQ ID NO:1.
 19. The composition of claim 17, wherein theother angiogenic polypeptide is selected from the group consisting ofFGF2, FGF4, FGF5, and PDGF-β.
 20. The composition of claim 17, whereinthe variant comprises an amino acid sequence having at least 80%identity with the amino acid sequence selected from the group consistingof: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.
 21. Thecomposition of claim 17, wherein the FGF-9 polypeptide comprises anamino acid sequence of SEQ ID NO:1.
 22. The composition of claim 17,wherein the other angiogenic polypeptide is FGF2.
 23. The composition ofany one of claims 17 to 22, wherein the animal is a mammal.
 24. Thecomposition of any one of claims 17 to 22, wherein the animal is amammal selected from the group consisting of mouse, pig, dog, rat, andhuman.
 25. The composition of claim 24, wherein the mammal is human. 26.A composition for promoting therapeutic angiogenesis in an animalcomprising a recombinant cell producing an isolated FGF-9 polypeptideand another isolated angiogenic polypeptide.
 27. The composition ofclaim 26, wherein the FGF-9 polypeptide comprises an amino acid sequenceselected from the group consisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ IDNO:3 and SEQ ID NO:4, or a variant thereof.
 28. The composition of claim27, wherein the FGF-9 polypeptide comprises an amino acid sequence ofSEQ ID NO:1 or a variant thereof that is at least 80% identical to theamino acid sequence of SEQ ID NO:1.
 29. The composition of claim 27,wherein the other angiogenic polypeptide is selected from the groupconsisting of FGF2, FGF4, FGF5, and PDGF-β.
 30. The composition of claim27, wherein the variant comprises an amino acid sequence having at least80% identity with the amino acid sequence selected from the groupconsisting of: SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3 and SEQ ID NO:4.31. The composition of claim 27, wherein the FGF-9 polypeptide comprisesan amino acid sequence of SEQ ID NO:1.
 32. The composition of claim 27,wherein the other angiogenic polypeptide is FGF2.
 33. The composition ofany one of claims 27 to 32, wherein the animal is a mammal.
 34. Thecomposition of any one of claims 27 to 32, wherein the animal is amammal selected from the group consisting of mouse, pig, dog, rat, andhuman.
 35. The composition of claim 34, wherein the mammal is a human.36. The composition of any one of claims 27 to 35, wherein therecombinant cell is a stem cell.
 37. The composition of any one ofclaims 1 to 36, further comprising a pharmaceutically acceptablecarrier.
 38. The composition of any one of claims 1 to 36, furthercomprising a chelating agent.
 39. The composition of any one of claims 1to 36, further comprising a preservative.
 40. A method of promotingformation of mature blood vessels in a subject comprising administeringan effective amount of the composition of any one of claims 1 to 39 tothe subject.
 41. A method of treating ischemia in a subject comprisingadministering an effective amount of the composition of any one ofclaims 1 to 39 to the subject.
 42. A use of the composition of any oneof claims 1 to 39 for preparation of a medicament.
 43. A use of thecomposition of any one of claims 1 to 39 for preparation of a medicamentfor promoting formation of mature blood vessels in a subject.
 44. A useof the composition of any one of claims 1 to 39 for preparation of amedicament for treating ischemia in a subject.
 45. A use of thecomposition of any one of claims 1 to 39 for promoting formation ofmature blood vessels in a subject.
 46. A use of the composition of anyone of claims 1 to 39 for treating ischemia in a subject.
 47. A kitcomprising the composition of any one of claims 1 to 39, andinstructions for administering the composition to a subject.
 48. Amethod of promoting formation of mature blood vessels in a subjectcomprising administering an effective amount of FGF-9 to the subject.49. A method of treating ischemia in a subject comprising administeringan effective amount of FGF-9 to the subject.
 50. A use of FGF-9 forpreparation of a medicament.
 51. A use of FGF-9 for preparation of amedicament for promoting for on of mature blood vessels in a subject.52. A use of FGF-9 for preparation of a medicament for treating ischemiain a subject.
 53. A use of FGF-9 for promoting formation of mature bloodvessels in a subject.
 54. A use of FGF-9 for treating ischemia in asubject.
 55. A kit comprising FGF-9, and instructions for administeringthe composition to a subject.
 56. A kit comprising FGF-9 and a matrixmaterial, and instructions for preparing an in vitro vasculogenesisassay.
 57. An in vitro vasculogenesis assay comprising a matrixmaterial, FGF-9, endothelial cells, smooth muscle cells, and a matrixmaterial for supporting growth and proliferation of all cells.
 58. Useof FGF-9 for stabilization of blood vessels in vitro or in vivo.
 59. Theuse of claim 58, wherein the blood vessels exhibit vascular leakage orare at risk of developing vascular leakage.
 60. The use of claim 58,wherein the blood vessels are within a tumour.
 61. The use of FGF-9 fortreatment of cancer.
 62. A composition for improving the condition of ablood vessel in an animal, the composition comprising an isolated FGF-9polypeptide and one or more other angiogenic polypeptides.